Abstract 417P
Background
An increasing amount of research suggests that the presence of minimal residual dis-ease (MRD) after curative-intent surgery for early-stage cancers is associated with disease recurrence. Circulating tumor DNA (ctDNA) has emerged as a promising biomarker for MRD assessment in patients with colorectal cancer (CRC) who have undergone surgery or completed adjuvant therapy. MRD tests are already available for use in clinics; however, treatment decisions following MRD results obtained in routine practice are infrequently described.
Methods
In this study, we report on the real-world clinical use of Guardant Reveal, a validated tissue-agnostic MRD assay which assesses genomic mutations as well as methylation sigantures, in the first 82 consecutive patients (102 samples) with CRC tested in Asia and the Middle East.
Results
Overall, 24% of patients had ctDNA detected in their first MRD test, and the frequency of ctDNA positivity increased with increasing tumor stage. Among all ctDNA-positive samples, 48% had evidence of MRD only through the detection of methylation signals, while 26% had both genomic alterations and methylation signals. In patients with stage II CRC, 78% of tests were ordered within 12 weeks after resection, while for patients with stage III disease, 63% of tests were ordered during surveillance. We also describe real-life clinical cases utilizing tissue-agnostic MRD assessment. Most of the physicians included MRD test results in the treatment pla.
Conclusions
Through retrospective analysis of real-world data, we describe how physicians in Asia and the Middle East currently apply a commercially available tissue-agnostic MRD assay in clinical decision-making for patients after surgical resection of colorectal cancer. The addition of methylation assessment to somatic mutation detection contributed to the detection of MRD in samples without mutation. Results from prospective randomized studies will further define the clinical role of MRD detection in resectable CRC. Evidence for tissue-agnostic MRD assays is building across tumor types with continuous improvements in sensitivity and specificity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
S.S. Jain, S. Hsing, N. Joshi: Financial Interests, Personal, Full or part-time Employment: Guardant Health. All other authors have declared no conflicts of interest.
Resources from the same session
26P - Subcutaneous trastuzumab versus intravenous trastuzumab for treatment of patients with HER2-positive breast cancer: A time, motion and cost-benefit assessment in a day care oncology unit in China
Presenter: Bei Sun
Session: Poster Display
Resources:
Abstract
27P - The biological characteristics of HER2-low in TNBC using mRNA profiling and molecular subtypes
Presenter: Asako Tsuruga
Session: Poster Display
Resources:
Abstract
28P - One-week ultra-hypofractionated partial breast RT in early breast cancer: 3DCRT vs IMRT
Presenter: Nurilla Zaynutdinov
Session: Poster Display
Resources:
Abstract
30P - Stereotactic body radiotherapy using cyberknife versus interstitial brachytherapy in accelerated partial breast irradiation on left-sided breast: A comparison of preliminary clinical result and dosimetric characteristics
Presenter: Ting-Na Wei
Session: Poster Display
Resources:
Abstract
31P - Prognostic implication of breast edema on preoperative breast MRI in breast cancer
Presenter: Ki-tae Hwang
Session: Poster Display
Resources:
Abstract
32P - Efficacy of olanzapine in the prophylaxis of delayed chemotherapy-induced nausea and vomiting in breast cancer patients receiving dose-dense AC with a steroid-sparing regimen: A single-center pilot study
Presenter: Manami Tada
Session: Poster Display
Resources:
Abstract
34P - Social support as the mediator of the association between unmet needs and happiness among women with early breast cancer
Presenter: Nithiya Sinarajoo
Session: Poster Display
Resources:
Abstract
35P - Prospective study assessing the efficacy and safety of a scalp cooling device for the prevention of alopecia in breast cancer patients undergoing (neo)adjuvant chemotherapy
Presenter: Winnie Yeo
Session: Poster Display
Resources:
Abstract
37P - To excise or not to excise: Preventive management of early breast cancer in atypical ductal hyperplasia patients
Presenter: Clarisse Hing
Session: Poster Display
Resources:
Abstract
38P - Exploring prognostic factors in patients achieving PCR after neoadjuvant therapy for triple-negative breast cancer: A retrospective study based on SEER data
Presenter: Lv Wenjie
Session: Poster Display
Resources:
Abstract